Biomarker Monitoring with Unrivaled Sensitivity and Specificity
Biomarker immunoassays are revolutionizing biopharmaceutical science and laboratory medicine. These antibody/antigen based assays have made possible the measurement of minute amounts of protein in a diverse array of biologically relevant samples. The sensitivity and specificity of traditional immunoassays is frequently limited by endogenous and exogenous interferences that cannot be eliminated and researchers struggle to identify and eliminate their effects.
AMMP® assays using non-optical detection offer protein researchers an easy-to-use platform that uniquely addresses biomarker testing needs with highly sensitive detection and quantitation in complex biological mixtures.
See how BioScale can help you achieve your research goals. To discuss your biomarker or protein analysis application contact us.
Rapid Biomarker Analysis in Urine
Presently, acute kidney injury is monitored by measuring an increase in Blood Urea Nitrogen (BUN) and creatinine. Unfortunately changes in BUN are usually only detectable after irreversible damage has been caused to the kidney. Urinary kidney injury molecule (KIM-1) is a sensitive quantitative biomarker for early detection of kidney tubular injury.The KIM-1 kidney biomarker is under study because this biomarker rapidly increases in urine and can indicate kidney damage when intervention is still an option. A study was done using the ViBE® Workstation running an AMMP® Assay versus a Luminex creatinine and ELISA assay to evaluate each technology and its feasibility to be used in a rapid 40 minute analysis. Using the methodology below, the ViBE® Workstation demonstrated comparable data to the Luminex and ELISA assays with three hour incubation times, however, the ViBE® also achieved the same results with only a 30 minute incubation time.







